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ARTICLE
Pathway engineering in yeast for synthesizing
the complex polyketide bikaverin
Meng Zhao 1,2,3, Yu Zhao 3, Mingdong Yao1,2, Hala Iqbal 3, Qi Hu1,2, Hong Liu1,2, Bin Qiao1,2, Chun Li 1,2,
Christine A. S. Skovbjerg 4, Jens Christian Nielsen5, Jens Nielsen 5,6, Rasmus J. N. Frandsen 4,
Yingjin Yuan 1,2 & Jef D. Boeke 3,7✉
Fungal polyketides display remarkable structural diversity and bioactivity, and therefore the
biosynthesis and engineering of this large class of molecules is therapeutically significant.
Here, we successfully recode, construct and characterize the biosynthetic pathway of bika-
verin, a tetracyclic polyketide with antibiotic, antifungal and anticancer properties, in S. cer-
evisiae. We use a green fluorescent protein (GFP) mapping strategy to identify the low
expression of Bik1 (polyketide synthase) as a major bottleneck step in the pathway, and a
promoter exchange strategy is used to increase expression of Bik1 and bikaverin titer. Then,
we use an enzyme-fusion strategy to directly couple the monooxygenase (Bik2) and
methyltransferase (Bik3) to efficiently channel intermediates between modifying enzymes,
leading to an improved titer of bikaverin at 202.75mg/L with flask fermentation (273-fold
higher than the initial titer). This study demonstrates that the biosynthesis of complex fungal
polyketides can be established and efficiently engineered in S. cerevisiae, highlighting the
potential for natural product synthesis and large-scale fermentation in yeast.
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Fungal polyketides represent a large group of structurally andfunctionally diverse natural products with clinically relevantmedical properties, including antibiotic, antifungal, immu-
nosuppression, and anticancer activities1–4. This diversity is
biosynthetically generated by the combination of modifying
enzymes, such as methyltransferases and oxygenases, and a
multifunctional enzyme polyketide synthase (PKS) that con-
denses multiple carboxyl units in a highly regulated, iterative
process involving initiation, elongation, cyclization, and release5.
Because the resulting molecules are often excellent candidates for
therapeutics, the metabolic engineering of fungal polyketides,
including both their biosynthesis and large-scale fermentation, is
of substantial interest.
Saccharomyces cerevisiae is one of the most widely used hosts
for the metabolic engineering of natural products including
antibiotics, terpenoids, cannabinoids, and opiates6–9. Despite the
genetic tractability and scalability of metabolic engineering in
yeast and a few examples of the successful biosynthesis of fungal
polyketides in S. cerevisiae, the biosynthesis and large-scale fer-
mentation of complex polyketides in yeast remains a challenge,
due to the large size of the PKS biosynthetic enzymes, compli-
cated biosynthetic pathways, and highly regulated nature of the
process10–14.
Bikaverin is a red-colored tetracyclic polyketide with anti-
bacterial and anticancer activities produced by members of the
genus Fusarium15–19. A putative bikaverin biosynthetic gene
cluster was identified in Fusarium fujikuroi, and a biosynthetic
pathway was proposed based on knockout-based studies. How-
ever, the pathway has not been fully characterized nor verified via
gain of function experiments. Among the six proteins encoded,
enzymes Bik1, Bik2, and Bik3 are predicted to be responsible for
the synthesis of bikaverin, while Bik4 and Bik5 are predicted
transcription regulators, and Bik6 is a permease18. The polyketide
carbon-skeleton of bikaverin is produced by the Type I PKS Bik1
(formerly called PKS4), which is a very large (over 2000 amino
acid residues) multifunctional enzyme consisting of the following
domains: starter unit acyltransferase (SAT), β-ketosynthase (KS),
malonyl:ACP acyltransferase (MAT), product template (PT),
acyl carrier protein (ACP), and thioesterase/claisen cyclase (TE/
CLC)20,21. The SAT domain initially selects acetyl-CoA as a
starting unit, and the KS and MAT domains condense eight
units of malonyl-CoA to the growing polyketide chain, resulting
in a polyketide chain, which is covalently tethered to the ACP
domain throughout chain elongation. The PT and TE/CLC
domains control and cyclize the chain, releasing the intermediate
pre-bikaverin from Bik1. Pre-bikaverin is modified with two
oxidations catalyzed by the FAD-dependent monooxygenase
Bik2, and two methylations catalyzed by O-methyltransferase
Bik3, to form the final product bikaverin (Fig. 1a). To expand
the metabolic engineering of polyketides in yeast, the bikaverin
pathway is an example of constructing and characterizing a
cell factory in S. cerevisiae for the production of this
fungal polyketide.
In this work, we successfully recode, construct, and char-
acterize the biosynthetic pathway of the complex polyketide
bikaverin in S. cerevisiae. We develop a GFP-mapping method for
quickly identifying the expression of bik1 as the bottleneck in the
pathway and use a promoter exchange strategy to increase
expression of bik1 and subsequently, bikaverin titer. In addition,
we verify the genes essential for bikaverin synthesis and char-
acterize the biosynthetic pathway through a bottom-up strategy.
Finally, we optimize bikaverin production by developing an
enzyme-fusion method to couple the modifying enzymes
Bik2 and Bik3 to create a short substrate channel between the
enzymes, achieving a ~270-fold increase in the final titer of the
molecule.
Results
Establishing the biosynthesis of bikaverin in S. cerevisiae. To
heterologously express the bikaverin biosynthetic pathway in S.
cerevisiae, we designed a yeast-recoded bikaverin gene cluster
comprising the genes bik1, bik2, bik3, and bik6, as well as the
coding genes of phosphopantetheinyl transferase (PPTase) needed
for post-translational activation of the ACP domain in Bik1. We
retrieved the protein sequences of Bik1, Bik2, Bik3, and Bik6 from
the NCBI Protein database: (accession numbers: Bik1, S0DZM7;
Bik2, S0E2X6; Bik3, S0E608; Bik6, S0DZN4)22. Protein sequences
were reverse-translated and codon-optimized for expression in S.
cerevisiae. Then, we synthesized these bik1, bik2, bik3, and bik6
genes under the control of yeast endogenous promoters, PRPS2,
PTEF1, PTPI1, and PPGK1, respectively (Fig. 1b). In addition, to
facilitate the post-translational activation of the PKS, we chose two
PPTases to activate Bik1: Ppt1 (accession number CCE73639), the
native PPTase from F. fujikuroi, and NpgA (accession number
AAF12814), a PPTase from A. nidulans, which has previously
been successfully used in yeast to activate PKSs and nonribosomal
peptide synthetases (NPRSs)6,12,13. Both PPTase genes were added
into the constructed yeast bikaverin expression cassette under the
control of PENO2 and PTEF2 promoters, respectively. The resulting
bikaverin expression cassette was transformed into yeast, as strain
yZM006. This strain, however, failed to turn red, and no bikaverin
was detected (Supplementary Fig. 1).
To probe the bottlenecks limiting biosynthesis in the bikaverin
pathway, we developed a GFP-mapping strategy to confirm that
all genes were well expressed (Fig. 2a). The coding sequence for
green fluorescent protein (GFP) was fused in frame to the 3′ end
of the individual genes. Fluorescent microscopy showed a strong
GFP signal in cells where the genes bik2, bik3, bik6, ppt1, or npgA
were tagged, whereas cells meant to express bik1 displayed a weak
signal, suggesting that the Bik1 level was limiting bikaverin
biosynthesis (Fig. 2b). Bik1 is a large and multidomain PKS
enzyme, roughly 220 kDa in size. We hypothesized that the
protein was either poorly expressed from our construct or
degraded in yeast because of its large size. To test this hypothesis,
we replaced the initial promoter PRPS2 with several different yeast
endogenous promoters: PRPL43A, PGPM1, and PGAL1. It was
observed that the Bik1-GFP was strongly expressed only when
driven by the galactose-inducible GAL1 promoter (strain
yZM018) (Fig. 2c). Consistent with this result, only strain
yZM009 turned red, and only when grown on galactose medium
(Supplementary Fig. 1). In order to further confirm Bik1
expression, we tagged Bik1 with poly-histidine and checked the
production and degradation of the protein by western blot.
Expression of Bik1 was much higher when it was driven by PGAL1
compared to other promoters, with partial protein degradation
detected (Fig. 2d, e). Finally, bikaverin synthesized was also
confirmed by HPLC and MS (Fig. 2f and Supplementary Fig. 2).
To further confirm that bikaverin biosynthesis was the
consequence of higher expression of Bik1, and not because of
the use of galactose instead of glucose as the carbon source, we
introduced a galactose-independent system to regulate the GAL1
promoter (Fig. 3a). In this system, a GAL4(1-93).ER.VP16 (GEV)
plasmid is expressed to produce a tribrid protein comprising a
Gal4 DNA-binding domain, an estrogen receptor and a VP16
domain23,24. This complex, when bound to β-estradiol (EST), will
translocate into the nucleus and bind to PGAL1 to activate
downstream gene transcription, and an increase in EST
availability will lead to higher rates of transcription23,24. With
bik1 under the control of this system, higher concentrations of
EST in the glucose medium resulted in higher expression of Bik1
and deeper red colony color (Fig. 3b). This confirmed that the
production of bikaverin indeed resulted from promoter exchange
to PGAL1 and the subsequent higher expression of bik1.
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Characterization of the bikaverin pathway in S. cerevisiae. With
bikaverin biosynthesis successfully established in S. cerevisiae, we
turned to the characterization of this biosynthetic pathway using
both top-down and bottom-up strategies. To probe the essenti-
ality of bik6 for bikaverin production in yeast and whether both
PPTases can activate Bik1, we used a top-down approach to
delete bik6, ppt1, and npgA separately or in combination, from
the yeast-recoded bikaverin pathway. Unlike in F. fujikoroi, where
deletion of bik6 was reported to reduce bikaverin yield, deletion of
bik6 in S. cerevisiae had minimal effect on bikaverin yield (Fig. 4a
and Supplementary Fig. 9). Conversely, when we deleted both
ppt1 and npgA, bikaverin was not synthesized at all, suggesting
there was no intrinsic PPTase in yeast that could activate Bik1 by
phosphopantetheinylation, whereas deletion of either ppt1 or
npgA reduced but did not eliminate bikaverin titers compared to
the original strain. The fact that bikaverin was still successfully
synthesized in both cases indicated that both Ppt1 and NpgA
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Fig. 1 Bikaverin biosynthetic pathway in S. cerevisiae. a In the bikaverin biosynthetic pathway, the polyketide synthase Bik1, activated by
phosphopantetheinyl transferase (PPTase), condenses one acetyl-CoA and eight malonyl-CoA units to form pre-bikaverin. The modifying enzymes Bik2
(monooxygenase) and Bik3 (O-methyl-transferase) convert pre-bikaverin into the final product bikaverin. The groups modified by Bik2 or Bik3 are
highlighted in red or purple, respectively. SAT, starter unit acyltransferase; KS, ketosynthase; MAT, malonyl:ACP acyltransferase; PT, product template;
ACP, acyl carrier protein; TE/CLC, thioesterase/claisen cyclase; SAM, S-adenosylmethionine; SAH, S-adenosylhomocysteine. b The constructed bikaverin
pathway encoding plasmid. The ppt1, npgA, and bik genes (bik1, bik2, bik3, bik6) were codon-optimized, synthesized, and assembled into the pRS416 plasmid
vector and transformed into S. cerevisiae.
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strains containing two copies of ppt1 or npgA showed a different
result: doubling ppt1 did not show improvement in bikaverin
titers compared to single copy of ppt1. But doubling npgA
improved the bikaverin production to a similar level as the ori-
ginal design containing both ppt1 and npgA (Supplementary
Fig. 3). This result suggests that NpgA may be a more effective
PPTase for activating the ACP domain of Bik1 in yeast.
To further characterize bikaverin biosynthesis and establish the
order of reactions in this pathway, we used a bottom-up strategy
to build constructs with different combinations of bik1, bik2, and
bik3 and analyzed the resulting intermediates using HPLC–MS25
(Fig. 4b). As expected, pre-bikaverin (m/z 325.06) (1) was
detected in all strains containing bik1 (Fig. 4b and Supplementary
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intermediate resulting from the C7 oxidation of pre-bikaverin by
the monooxygenase Bik2, was detected in strains containing bik2
(yZM027 and yZM009). Interestingly, di-nor-bikaverin, the
predicted product from the further oxidation of oxo-pre-
bikaverin, was not detected in either strain expressing Bik2
(yZM027 and yZM009), indicating that in yeast the monoox-
ygenase cannot oxidize the C6 position without prior oxidation of
the C7 position (Supplementary Fig. 6).
In the strain containing only bik1 and bik3 (yZM028), two
small peaks of m/z 339.09 and 339.08 were detected (Supple-
mentary Fig. 7). HPLC–MS retention time confirmed that neither
peak was oxo-pre-bikaverin (2), and neither peak was detected in
strains that are lacking bik3. We speculated that these peaks are
intermediates resulting from Bik3-catalyzed methylation of pre-
bikaverin to form C8-me-pre-bikaverin (3) and C3-me-pre-
bikaverin (4). These two peaks were small and not detected in
strain yZM009 containing the entire pathway, suggesting that
pre-bikaverin can be methylated by Bik3 but that this substrate
may not be preferred by Bik3, compared to oxo-pre-bikaverin (2)
and other downstream substrates including C3/C8 me-oxo-pre-
bikaverin (6/5) and nor-bikaverin (8).
In strain yZM009 containing all the pathway genes, pre-
bikaverin (1) and oxo-pre-bikaverin (2) were detected (Supple-
mentary Fig. 8a and b). In addition, two peaks of m/z 353.05 were
detected (Supplementary Fig. 8c); these were postulated to be the
two mono-methylated forms of oxo-pre-bikaverin: C3-me-oxo-
pre-bikaverin (6) and C8-me-oxo-pre-bikaverin (5). In addition,
a peak corresponding to dehydroxy-bikaverin (m/z 367.07) (7),
the di-methylated form of oxo-pre-bikaverin, was detected in this
strain (Supplementary Fig. 8d), suggesting that Bik3 is able to
methylate oxo-pre-bikaverin twice in yeast. Nor-bikaverin (8), the
intermediate produced from the further oxidation of C8-me-oxo-
pre-bikaverin (5) by Bik2, was also detected (m/z 369.05) and
confirmed by comparison to the previously published MS trace of
the molecule25. However, at m/z 369.05, only one peak of nor-
bikaverin was detected, which suggested that C8-me-oxo-pre-
bikaverin, not C3-me-oxo-pre-bikaverin, was the favored sub-
strate of bik2, although it is possible that the oxidized form of C3-
me-oxo-pre-bikaverin cannot be isolated using the HPLC–MS
conditions tested (Supplementary Fig. 8e). With this certain
preference for substrates, Bik2 can catalyze the oxidation of C8-
me-oxo-pre-bikaverin, while Bik3 can methylate both C3-me-
oxo-pre-bikaverin and C8-me-oxo-pre-bikaverin in S. cerevisiae.
The final product, bikaverin (m/z 383.06) (9), was only detected
in the strain containing the complete pathway, confirming that
Bik1, Bik2, and Bik3 are all essential and sufficient for the de novo
biosynthesis of bikaverin (Supplementary Figs. 4 and 8f).
Based on these results, we mapped out the putative bikaverin
biosynthetic pathway in yeast (Fig. 4c). Pre-bikaverin is first
oxidized to oxo-pre-bikaverin by Bik2, then to dehydroxy-
bikaverin by two methylation steps catalyzed by Bik3.
Dehydroxy-bikaverin can then be oxidized by Bik2 again to
form the final product bikaverin. In addition, the intermediate
C8-me-oxo-pre-bikaverin, but not C3-me-oxo-pre-bikaverin, can
Fig. 2 Identifying bottlenecks in the bikaverin pathway. a GFP-mapping strategy to identify bottlenecks. Each bikaverin pathway gene (in gray) was
tagged with GFPtag (in green) separately to check their expression and Bik1 was identified as the bottleneck in the pathway. b The results of fluorescence
checking in GFP-mapping strategy. Scale bar= 20 µm. c Fluorescence of Bik1-GFP using different promoters. Scale bar= 50 µm. d Western blots to check
expression of C-terminally His-tagged Bik1 using different promoters. GAPDH was used as the internal reference protein. The original uncropped source
image is provided in Supplementary Fig. 12. e Quantitative relative expression level of Bik1 using these promoters. Relative expression level was the
intensity of Bik1 band divided by the intensity of internal reference GAPDH band. Data are presented here as mean values ± standard deviation (SD)
calculated from n= 3 biological replicates. f The production of bikaverin in strain yZM009 was confirmed by HPLC analysis. Experiments in b–d were
















































b No EST 3 nM EST 10 nM EST 30 nM EST 50 nM EST 100 nM EST








Fig. 3 Using the GEV system to regulate Bik1 expression and its effect on bikaverin synthesis. a Working principle diagram of GEV system. The GEV
inducible system regulates the GAL1 promoter to express Bik1 by β-estradiol (EST). In this system, GEV–EST complex will activate transcription from the
GAL1 promoter and increasing the concentration of β-estradiol in the glucose medium leads to stronger expression. b Using GEV system to regulate Bik1
expression. Spot assays were performed to check bikaverin production on SC-Ura-His plates with a gradient of estradiol concentration. The empty pRS413
and pRS416 plasmids were co-transformed into BY4741 as the empty control. The strains yZM006 (with PRPS2-bik1) and yZM009 (with PGAL1-bik1) were
transformed with the GEV plasmid, generating strains yZM021 and yZM022, respectively.
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also be oxidized by Bik2 to nor-bikaverin and then methylated by
Bik3 to form bikaverin.
Pathway optimization to increase bikaverin production.
Although the biosynthetic pathway of bikaverin was reconstituted
in S. cerevisiae, titers of the molecule remained low. To further
optimize the pathway in yeast, we applied the promoter exchange
strategy described earlier to modifying enzymes in the bikaverin
pathway. It was found that changing the promoter of bik2 or bik3
to PGAL1 resulted in an increase in bikaverin titer from ~0.74 to
~2.90 mg/L or to ~1.37 mg/L, respectively (Fig. 5a). Further,
changing both bik2 and bik3 promoters to PGAL1 resulted in a
bikaverin titer of ~3.65 mg/L, as in strain yZM031, which was
five-fold higher than the original strain yZM009.
In addition, characterization of the bikaverin biosynthetic
pathway highlighted that pre-bikaverin is modified in a stepwise
manner by the monooxygenase Bik2 and the O-methyltransferase
Bik3. Interestingly, substrates need to shuttle repeatedly between
Bik2 and Bik3 to convert oxo-pre-bikaverin to bikaverin. We
hypothesized that repeated substrate-shuttling may limit the
synergistic catalytic efficiency of Bik2 and Bik3. Thus, we
reasoned that we could increase the catalytic efficiency of Bik2
and Bik3 by fusing them to form a short and adaptive substrate
channel for simplifying substrate transfer between these two
enzymes and preventing the diffusion of undesirable complex
substrates.
To test this, we first built the fusion protein of Bik2 and Bik3
(Bik2–Bik3) with a (GGGS)3 linker connecting the C-terminus of
Bik2 to the N-terminus of Bik3. As a result, the titer of bikaverin
significantly increased to ~41.4 mg/L in the strain yZM037
containing Bik2–Bik3, ~11-fold higher than that in the strain
yZM031 with separate Bik2 and Bik3, and nearly 60-fold higher
than that in the original strain producing bikaverin (yZM009)
(Fig. 5a). Conversely, the pathway using the reverse fusion
protein connecting the N-terminus of Bik2 to the C-terminus of
Bik3 (Bik3–Bik2) in strain yZM042 showed no production of
bikaverin (Fig. 5a). To understand these two results, we modeled
the protein structures of the two Bik2–Bik3 fusion constructs. The
active site and FAD-binding pocket of Bik2 are near its N-
terminal, while the active site and SAM-binding pocket of Bik3
are close to C-terminal (Supplementary Fig. 10). The fusion of
Bik3–Bik2 is postulated to disturb the active pocket structures of
Bik2 and Bik3. This could be the reason that no detectable
bikaverin was produced in the Bik3–Bik2 strain. To check the
effect of protein fusion on the stability of the fusion proteins, we
a
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Fig. 4 Characterization of bikaverin synthesis in yeast. a A top-down strategy was used to measure the effects of bik6, ppt1, and/or npgA deletion on
bikaverin production. Data are presented here as mean values ± SD calculated from n= 3 biological replicates. b As a bottom-up strategy, pathways
containing different combinations of bik1, bik2, and bik3 were constructed. The intermediates (1–9 as in c) was detected by HPLC–MS (Supplementary
Figs. 5–8) and used to decipher the biosynthetic pathway of bikaverin. c The putative bikaverin biosynthesis pathway in S. cerevisiae. Multi-domain protein
Bik1 is displayed as a series of connected red rectangles. Boxed intermediates were only detected in the absence of bik2 (Supplementary Fig. 6). Source
data underlying a are provided as a Source Data file.
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tagged Bik2, Bik3, Bik2–Bik3, and Bik3–Bik2 with poly-His tags
and checked expression levels using western blots (Supplemen-
tary Fig. 11). We found that the expression of Bik2–Bik3 and
Bik3–Bik2 was similar to Bik2 or Bik3, with both fusion proteins
expressed at slightly lower levels (Fig. 5c). This confirmed that the
improved titers of bikaverin seen were due to the fusion of
Bik2–Bik3, and not expression level or protein stability change.
We speculate that the Bik2–Bik3 fusion leads to a steric effect in
which a substrate-shuttle channel between Bik2 and Bik3 allows
substrates to transfer efficiently between Bik2 and Bik3, resulting
in improved bikaverin titers.
In order to further improve the titer, we changed the
fermentation medium from synthetic medium (SC–Ura) to rich
medium (YP+ galactose). Bikaverin titer rose to 131.48 mg/L
when yZM037 was cultured in YP medium with 20 g/L galactose
as carbon source. With galactose concentration increased to 40 g/
L, the titer was further improved to 202.75 mg/L, about a 273-fold
increase compared to the original titer (Fig. 5d).
Discussion
Fungal polyketides display remarkable structural and functional
diversity and are excellent candidates for the development and
biosynthetic engineering of new therapeutics with anticancer,
antifungal, antibiotic, and immunomodulation properties. In this
study, we demonstrated the efficient biosynthesis of the complex
fungal polyketide bikaverin in the heterologous host S. cerevisiae
using synthetic biology approaches. To achieve this, we recon-
structed the bikaverin pathway in yeast by recoding and syn-
thesizing the genes bik1, bik2, bik3, and bik6 from F. fujikoroi
along with two PPTases to activate the ACP domain of the
PKS Bik1.
Compared to bacteria, yeast is a better model organism for
biosynthetic engineering of fungal polyketides, with many available
synthetic biological tools including pathway assembly, CRISPR
genome editing and even whole chromosome synthesis, and
SCRaMbLE26–32. Using these tools available in yeast, we were able
to characterize the bikaverin biosynthetic pathway using top-down
and bottom-up strategies. Our result showed that genes bik1, bik2,
and bik3 are essential for the production of bikaverin, while in yeast,
omitting the permease encoding gene bik6 had minimal effect.
We also successfully confirmed the production of the proposed
intermediates in the bikaverin biosynthetic pathway and deter-
mined the reactions catalyzed by Bik2 and Bik3. In addition, the use
of yeast promoters to drive the expression of individual bikaverin













































































































Fig. 5 Optimization to improve bikaverin titer using promoter exchange and enzyme fusion strategies. a Driving bik2 and bik3 using PGAL1 led to a
modest increase (yZM031). Promoters used are shown in different color rectangles. Fusing Bik2 and Bik3 led to a dramatic increase in bikaverin titer
(yZM037), 60-fold higher than the original strain (yZM009). The strain with the ‘opposite polarity’ fusion as Bik3–Bik2 produced no bikaverin (yZM042).
b Substrates channel model between Bik2 and Bik3. The fusion of Bik2 and Bik3 may form a short and adaptive substrate channel. c Relative protein
expression levels of Bik2–His6, Bik3–His6, fusion proteins Bik3–Bik2–His6 and Bik2–Bik3–His6 using PGAL1 promoter by quantitative western blotting. Each
protein was fused with 6×His-tag at its C-terminus. Protein expression level was measured as the intensity of target protein band divided by the intensity of
the GAPDH band. d The bikaverin titer from flask fermentation. Strain yZM037 was cultured in YP medium supplemented with 20 or 40 g/L galactose as
the carbon source. Data in a, c, d are presented as mean values ± SD from n= 3 biological replicates. Source data underlying a, c, and d are provided as a
Source Data file.
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pre-existing transcription regulatory mechanisms in F. fujikuroi. In
summary, our strains display stable, tunable, and scalable bikaverin
production unaffected by environmental conditions, an added
advantage of using yeast as a host for polyketide bioengineering.
Finally, we were able to achieve titers of more than 200mg/L using
flask fermentation without modifying any yeast endogenous genes.
By establishing and optimizing the bikaverin pathway, we have
demonstrated effective and practical methods for the metabolic
engineering of polyketides in yeast. Establishing an effective meta-
bolic pathway is the first step for the metabolic engineering of
heterologous expression. It is common that reconstituted pathways
do not produce the desired molecule in heterologous hosts, and it is
often difficult to figure out the bottleneck step. In our study, a GFP-
mapping strategy helped us to identify Bik1 as the initial bottleneck
step quickly and efficiently. Based on this result, we debugged the
polyketide pathway and further improved the bikaverin titer by
testing several promoters and using the strong, inducible promoter
PGAL1 finally. This method can be used to figure out bottlenecks in
many other metabolic pathways. In addition, we used an enzyme-
fusion strategy to create a substrate channel between two modifying
enzymes. We postulated that this fusion may help channel sub-
strates from one modifying enzyme to the other, minimizing dif-
fusion of intermediates and improving efficiency of substrate
transfer between the two enzymes. In other biosynthetic pathways
with modifications, such as methylation, glycosylation, and hydro-
xylation that employ similar shuttling, this protein fusion strategy
might be key to improving product titers33–36.
In conclusion, we have demonstrated the potential of S. cerevisiae
to synthesize complex polyketides in this study. With more and
more PKS successfully expressed in yeast, we anticipate the
expansion of metabolic engineering of PKS in S. cerevisiae,
including the development of methods in yeast, such as domain
swapping to generate diverse polyketides. It has been reported that
swapping domains among different PKSs results in diverse func-
tions in vitro37–39. We hope that our study, as well as other pre-
existing synthetic biology tools, will result in the use of
S. cerevisiae as a robust platform to explore the chemical develop-
ment of polyketides and therapeutic applications with their diverse
bioactivities.
Methods
Yeast strains and plasmid assembly. All strains, plasmids used in this study were
listed in Supplementary Tables 1 and 2. The protein sequences of Bik1, Bik2, Bik3,
Bik6, Ppt1, and NpgA were obtained from the NCBI database (accession numbers:
Bik1, S0DZM7; Bik2, S0E2X6; Bik3, S0E608; Bik6, S0DZN4; Ppt1, CCE73639; NpgA,
AAF12814). Protein sequences were reverse-translated into nucleotide sequences and
codon optimized for expression in yeast using online tool BioPartsBuilder40. The
recoded DNA sequence is provided in Supplementary Data 1. Yeast promoters and
terminators were PCR amplified from BY4742 genomic DNA. All pathway genes
(bik1, bik2, bik3, bik6, ppt1, npgA) were individually constructed as transcription units
(TUs) consisting of promoter, coding sequence, and terminator employing the yeast
Golden Gate (yGG) DNA assembly method41. We used the versatile genetic assembly
system (VEGAS) to assemble all the TUs into pRS416 plasmid backbone in BY4742
(MATα ura3Δ0 leu1Δ0 lys2Δ0 his3Δ1)42,43. The final construct was miniprepped from
yeast and transformed into E. coli for sequencing verification and storage. The correct
plasmid with the complete bikaverin pathway was re-transformed into new
BY4742 strains for further study.
Yeast strains were grown using YPD-rich medium or defined SC media with
appropriate components dropped out or compounds added as indicated. All yeast
transformations in this study were performed with standard lithium acetate
protocols43.
Fusion protein construction in GFP-mapping strategy and western blot. To add
a GFP tag to the C-terminal of each coding sequence, the GFP-KanMX6 fragments
were PCR amplified with corresponding homology arms. Plasmid pFA6a-GFP(S65T)-
kanMX6 was used as PCR template and the primers used are listed in Supplementary
Table 3. Then the PCR amplicon was transformed into the yeast strain already car-
rying the complete bikaverin pathway. Successful integration was selected on YPD+
G418 plates and confirmed by colony PCR and Sanger sequencing.
To add a 6 × His tag to the C-terminal of each coding sequence, the 6 × His-
KanMX6 fragment was PCR amplified from plasmid pFA6a-GFP(S65T)-kanMX6
with primer His-tag-F and His-tag-R at first. Then the first round PCR amplicon
was used as PCR template for amplifying the fragments added with corresponding
homology arms. The corresponding primers are shown in Supplementary Table 3.
Then the second round PCR amplicon was transformed into the yeast strain as
above. And successful integration was selected on YPD+G418 plates and
confirmed by colony PCR and Sanger sequencing too.
Fluorescence microscopy. Pictures were taken using an EVOS-FL Auto cell
imaging system (Invitrogen) with the ×20 objective lens. Yeast cells were cultured
on plates using appropriate selective media for 2 days, then picked onto wet mount
slides for visualization.
Strain fermentation and bikaverin extraction. Yeast strains were cultured in 5mL
of SC–Ura liquid medium at 30 °C, overnight to saturation. Cells were harvested by
centrifugation at 1600×g for 5min, followed by 3 × 2mL washes with water, then
inoculated to an initial A600 of 0.5 in 30mL of SC–Ura liquid medium with either
glucose or galactose as the carbon source. Cultures were incubated at 30 °C for 96 h.
Appropriate volumes of cell cultures (2 mL for Bik2–Bik3 fusion strains, 10 mL for
other strains) were centrifuged for 10min at 13,800×g. Cell pellets were resuspended
with 0.5mL water in a 2mL tube, and 200 µL of acid-washed glass beads (Sigma,
G8772-100G) were added into the tubes along with 0.5mL ethyl acetate and 0.5 µL
formic acid. Resulting suspensions were vortexed for 20min and centrifuged for
10min at 13,800×g before the supernatant was transferred to a new tube; this was
repeated for five times. Finally, extracts were dissolved in 500 µL acetonitrile (ACN)
and centrifuged for three times at 13,800×g, 10min. Resulting extracts were used for
HPLC and HPLC–MS analysis.
HPLC analysis. HPLC analysis of bikaverin was performed on a Waters 2695 system
equipped with a 2489 UV detector operating at 510 nm. Separation was achieved
using a HyPURITY C18 5 μm 150 × 4.6mm column (Thermo Fisher, 22105-154630)
at 25 °C. The HPLC program was as follows: ACN as solvent A and 0.1% formic acid
as solvent B; flow rate 0.8mL/min; injection volume 20 µL; 0min 30%A/70%B, 3min
30%A/70%B, 5 min 35%A/65%B, 20min 65%A/35%B, 25min 80%A/20%B, 30min
80%A/20%B, 30.5min 30%A/70%B, and 45min 30%A/70%B. Bikaverin standards
(Sigma, SML0724) at the following concentrations: 60, 30, 15, 7.5, 3.75, 1.87 µg/mL,
were used to establish a standard curve to calculate yields.
LC/ESI–MS analysis. All MS data was measured by a HPLC/ESI–MS method.
Bruker micrOTOF-Q II instrument connected with Agilent HPLC system (Agilent
G1312B SL binary; Agilent G1367C SL WP) were used to detect bikaverin and
pathway intermediates. The HPLC program and column used here were the same as
the method used in HPLC analysis. Electrospray ionization (ESI) mass spectrometry
was performed in positive mode and set as follows: voltage set capillary at 4500 V, set
end plate offset at −500 V; nebulizer 2.0 bar; dry heater 180 °C; dry gas 6.0 l/min. The
mass data was analyzed using Compass Data Analysis software. Water Empower
3.0 software was used to analyze chromatography data.
Western blot. To quantify protein expression by western blot, a polyhistidine-tag
(6 ×His-tag) was attached to C terminals of each protein. Strains were cultured in
SC–Ura medium with the appropriate carbon source at 30 °C for 20 h. Then 10 A600
units of yeast cell were harvested, washed by water and resuspended by 500 μl of 0.3
M NaOH. After incubation at room temperature for 5min, cells were washed with
500 μl water, spun down and resuspended in 100 μl lysis buffer (4% β-mercap-
toethanol, 0.06M Tris–HCl, pH 6.8, 2% SDS, 5% glycerol), boiled for 10min and
centrifuged again at highest speed (14,000×g). After protein quantification by Brad-
ford method, 10 μl supernatant (containing ~40 μg total protein) was loaded per lane
of 12% SDS–PAGE gel. Proteins were transferred to a PVDF membrane and blocked
by 5% BSA buffer. Anti-His antibody (1:2000, TransGen HT501, China) and anti-
GAPDH antibody (1:2000, TransGen HC301, China) were used to probe target
proteins and internal reference protein GADPH. Goat anti-mouse IgG (H+ L) HRP-
conjugated antibody (1:3000, TransGen HS201, China) was used as the secondary
antibody. Multi-Chemiluminescent Blot Imaging System (Tanon-4800, China) was
used for image collection. ImageJ software was used to quantify the intensities of
protein bands (https://imagej.nih.gov/ij/).
Homology modeling and structural analysis in silico. To explore the effect of
protein fusion Bik2 and Bik3, the structure models of Bik2, Bik3 were built and
optimized using EasyModeller (Version 4.0)44. The high-resolution complex struc-
tures of rifampicin monooxygenase with FAD (PDB ID: 5KOW) and methyl-
transferase with SAM (PDB ID: 5w7p-A) were used as the templates of Bik2 and Bik3,
respectively. Modeled structures were analyzed using Pymol software (Version 1.7)45.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Data supporting the findings of this work are available within the paper and
its Supplementary Information files. A reporting summary for this Article is available as
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a Supplementary Information file. The datasets and materials generated and analyzed
during the current study are available from the corresponding author upon request. The
protein sequences of Bik1, Bik2, Bik3, Bik6, Ppt1, and NpgA were obtained from the
NCBI Protein database (accession numbers: Bik1, S0DZM7; Bik2, S0E2X6; Bik3, S0E608;
Bik6, S0DZN4; Ppt1, CCE73639; NpgA, AAF12814). Their DNA sequences used in this
study were provided in Supplementary Data 1. The templates of Bik2 and Bik3 used for
homology modeling were obtained from RCBS-PDB database (PDB ID: 5KOW and
5W7P-A, respectively). The LC–MS spectra data are available in Supplementary Figs. 4–
8. Source data are provided with this paper.
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